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Type 2 diabetes mellitus (T2DM) is a progressive disease that 
is characterized by insulin resistance and decreased insulin se-
cretion [1]. Based on data from the UK Prospective Diabetes 
Study (UKPDS), there is consensus regarding the importance 
of glycemic control in patients with T2DM [2]. The American 
Diabetes Association (ADA) considers general glycemic con-
trol to be represented by HbA1c below 7.0% [3]. The ADA and 
European Association for the Study of Diabetes (EASD) state-
ment on the management of hyperglycemia in T2DM patients 
recommends metformin intervention at the time of diagnosis 
in combination with lifestyle changes, and continuing timely 
augmentation of therapy with additional agents to achieve and 
maintain the recommended levels of glycemic control [4]. 
  Sitagliptin is an oral, selective dipeptidyl peptidase-4 (DPP-4) 
inhibitor that is used for the treatment of patients with T2DM 
[5]. Sitagliptin delays the enzymatic degradation and inactiva-
tion of glucagon-like peptide-1 (GLP-1) and glucose-depen-
dent insulinotropic peptide (GIP), the major incretins involved 
in glucose homeostasis, thereby increasing insulin release and 
lowering glucagon secretion in a glucose-dependent manner   
[5,6]. Incretin-based therapies are currently recommended as 
add-on therapy, when metformin  treatment  alone is not suf-
ficient to reach the ADA/EASD HbA1c target.
  Treatment with sitagliptin 100 mg once daily leads to im-
provements in glycemic control in patients with T2DM, in-
cluding reductions in HbA1c 0.6 to 0.7% [7]. The combined use 
of sitagliptin and metformin is an effective method of lower-
ing glucose levels in T2DM. The reduction in HbA1c was 1.1% 
with metformin (2,000 mg/day) alone, and 1.9% with sita-
gliptin/metformin (100 mg/2,000 mg) [8]. When sitagliptin 
(100 mg) was added to ongoing sulfonylurea therapy alone or 
to a combination of sulfonylurea/metformin, HbA1c levels 
were reduced by only 0.3% and 0.6%, respectively, whereas 
only 11% and 23% of patients, respectively, achieved HbA1c 
<7% at the end of 24 weeks [9]. 
  However, some studies have attempted to identify which 
patients respond to sitagliptin with better glycemic control 
among Korean T2DM patients. In this issue, ‘Predictive clini-
cal parameters for the therapeutic efficacy of sitagliptin in Ko-
rean type 2 diabetes mellitus’ by Kim et al. [10] evaluates clini-
cal factors associated with the therapeutic efficacy of sita-
gliptin when added to on oing metformin or metformin and 
sulfonylurea combination therapies. Kim et al. found that pa-
tients with more than a 20% decrease in fasting glucose and 
over 10% decrease in glycated hemoglobin after 24 weeks of 
sitagliptin administration, were younger and had lower body 
mass index (BMI) compared to non-responders. Treatment 
with 100 mg sitagliptin with metformin, or metformin and 
sulfonyurea for 24 weeks, led to additional reduction of mean 
HbA1c to 1.23±1.15%. This glycemic lowering effect is more 
potent than that observed in other previous studies [8,9]. In ad-
dition, the HbA1c lowering effect of sitagliptin was better in 
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non-obese patients and in patients with decreased insulin se-
cretion compared with the non-responder group.
  Recently, beta cell dysfunction and reduction in maximal 
capacity to secrete insulin were demonstrated to be primary 
metabolic defects in patients with T2DM [11]. In particular, 
studies have suggested that beta cell dysfunction may be espe-
cially important in the development of T2DM  in Korean pa-
tients [12]. These findings suggest that greater response to si-
tagliptin is expected in Korean T2DM patients with relative 
pancreatic secretory dysfunction in early phases of disease. 
  Sitagliptin is reported to be weight-neutral in clinical trials, 
and incidences of hypoglycemia and gastrointestinal adverse 
experiences in response to sitagliptin are similar to placebo 
[13]. In addition to its beneficial effects on glycemic control, 
sitagiptin, or combination treatment with sitagliptin and met-
formin, preserved beta cell function and beta cell integrity in 
Zucker diabetic fatty rats [14]. 
  Kim et al.’s study was retrospective, and did not control for 
other factors that affect glucose control. Despite these limita-
tions, their study is meaningful because it shows that early 
DPP-4 inhibitor initiation is a potential treatment option in 
younger, non-obese Korean T2DM patients whose glucose is 
not well controlled by metformin. As Kim et al. noted, further 
randomized, controlled prospective studies are needed.
  We would like to express our gratitude to Kim et al. for con-
ducting this study, and expect that expansion on these find-
ings will yield even more useful results. 
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